Physician profile
Fortuna Marc
NPI 1952063455
$1,135.78
in general payments reported to CMS, 2019-2025
14 companies · $844 in 2025
The $844 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $225 · 2023: $49.01 · 2024: $17.70 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $312.50 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $122.55 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $121.85 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $108.27 | 2025 | Shingrix |
| Lilly USA, LLC | $96.24 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Rgh Enterprises LLC | $92.18 | 2025 | |
| Tactile Systems Technology INC | $84.86 | 2025 | Nimbl, Flexitouch Plus |
| Dexcom, INC. | $75.43 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $33.95 | 2022-2023 | Nexplanon |
| Exact Sciences Corporation | $32.75 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $16.53 | 2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Averitas Pharma INC. | $14.25 | 2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.21 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fortuna Marc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.